Myeloproliferative neoplasm medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} {{AE}} {{MJK}} | {{CMG}} {{AE}} {{MJK}} | ||
==Overview== | ==Overview== | ||
The mainstay of therapy for myeloproliferative neoplasm is [[chemotherapy]], [[aspirin]], and palliative care.<ref name="cancergov">National Cancer Institute. Physician Data Query Database 2015.http://www.cancer.gov/types/leukemia/hp/cml-treatment-pdq#section/_19</ref><ref>{{Cite journal | The mainstay of therapy for myeloproliferative neoplasm is [[chemotherapy]], [[aspirin]], and palliative care. Treatment is directed at reducing the excessive numbers of blood cells.<ref name="cancergov">National Cancer Institute. Physician Data Query Database 2015.http://www.cancer.gov/types/leukemia/hp/cml-treatment-pdq#section/_19</ref><ref>{{Cite journal | ||
| author = [[A. Schmoldt]], [[H. F. Benthe]] & [[G. Haberland]] | | author = [[A. Schmoldt]], [[H. F. Benthe]] & [[G. Haberland]] | ||
| title = Digitoxin metabolism by rat liver microsomes | | title = Digitoxin metabolism by rat liver microsomes | ||
| Line 13: | Line 13: | ||
| month = September | | month = September | ||
| pmid = 10 | | pmid = 10 | ||
}}</ref> | }}</ref><ref name="cancergov">National Cancer Institute. Physician Data Query Database 2015.http://www.cancer.gov/types/myeloproliferative/hp/chronic-treatment-pdq</ref> | ||
==Medical Therapy== | ==Medical Therapy== | ||
Medical therapy for myeloproliferative neoplasm include:<ref>{{Cite journal | |||
| author = [[A. Schmoldt]], [[H. F. Benthe]] & [[G. Haberland]] | | author = [[A. Schmoldt]], [[H. F. Benthe]] & [[G. Haberland]] | ||
| title = Digitoxin metabolism by rat liver microsomes | | title = Digitoxin metabolism by rat liver microsomes | ||
| Line 25: | Line 25: | ||
| month = September | | month = September | ||
| pmid = 10 | | pmid = 10 | ||
}}</ref> | }}</ref><ref name="cancergov">National Cancer Institute. Physician Data Query Database 2015.http://www.cancer.gov/types/myeloproliferative/hp/chronic-treatment-pdq</ref> | ||
*[[Chemotherapy]] | |||
*[[Aspirin]] | |||
*Palliative care. | |||
==References== | ==References== | ||
Revision as of 17:04, 6 November 2015
|
Myeloproliferative Neoplasm Microchapters |
|
Differentiating myeloproliferative neoplasm from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Myeloproliferative neoplasm medical therapy On the Web |
|
American Roentgen Ray Society Images of Myeloproliferative neoplasm medical therapy |
|
Directions to Hospitals Treating Myeloproliferative neoplasm |
|
Risk calculators and risk factors for Myeloproliferative neoplasm medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
The mainstay of therapy for myeloproliferative neoplasm is chemotherapy, aspirin, and palliative care. Treatment is directed at reducing the excessive numbers of blood cells.[1][2][1]
Medical Therapy
Medical therapy for myeloproliferative neoplasm include:[3][1]
- Chemotherapy
- Aspirin
- Palliative care.
References
- ↑ 1.0 1.1 1.2 National Cancer Institute. Physician Data Query Database 2015.http://www.cancer.gov/types/leukemia/hp/cml-treatment-pdq#section/_19
- ↑ A. Schmoldt, H. F. Benthe & G. Haberland (1975). "Digitoxin metabolism by rat liver microsomes". Biochemical pharmacology. 24 (17): 1639–1641. PMID 10. Unknown parameter
|month=ignored (help) - ↑ A. Schmoldt, H. F. Benthe & G. Haberland (1975). "Digitoxin metabolism by rat liver microsomes". Biochemical pharmacology. 24 (17): 1639–1641. PMID 10. Unknown parameter
|month=ignored (help)